High-throughput CRISPR/Cas9 knockout screens in ALK-positive NB cells have revealed genes whose loss reduces sensitivity to ALK tyrosine kinase inhibitors, providing insight into resistance pathways [70]. The gene discussed is ALK; the disease is neuroblastoma.